


Whole Genome Sequencing in Multiple System Atrophy



MODIMSA Meeting
October 6th, 2018
Sonja W. Scholz, MD PhD
sonja.scholz@nih.gov



Overview



NIH Genome Sequencing Projects:

- a) Lewy body dementia (LBD) (n=3,000; ongoing)
- b) Neurologically Healthy, Aged Controls (n=2,000; ongoing)
- c) **Multiple system atrophy (MSA) (n=1,000; start: 2018)**



Objectives:

- a) To extend gene discovery efforts to the broader synucleinopathy spectrum
- b) To generate a genomic resource that is openly accessible to the research community



Genome Sequencing



We would like to request sample contributions

Inclusion criteria:

- European-ancestry MSA patients
- Definite or probable MSA per Gilman criteria

Exclusion criteria:

- if de-identified genomes cannot be shared via dbGaP and AMP-PD

Genome Sequencing



Samples:

- 3 μ g of DNA/patient required
- Alternatively, 3 mL of EDTA blood, saliva, or brain tissue are also acceptable



Shipping:

- paid by NIH

Genome Sequencing



State-of-the-art sequencing



Illumina X10

(150 bp, paired-end, 30x coverage)
(single library, single lane clustering)



Timeline:

- Sample recruitment: started Sept. 2018
- Sequencing: summer 2019
- Analysis/release of data: early 2020



All genomes will be available at AMP-PD, dbGaP at no cost



Contributors will be named authors on resulting publications



Contact

▶ If you are interested in participating or have any questions, please contact

Sonja Scholz (sonja.scholz@nih.gov)

National Institute of Neurological Disorders and Stroke

National Institute of Health

35 Convent Drive, Room 1A-1000

Bethesda, MD 20892, USA

